Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Ruxolitinib

Brand: 
NICE TA: 356 (terminated)
Indication: Polycythaemia vera (NICE TA356 - terminated appraisal)
Disease category: Nutrition and blood
Commissioning responsibility: 
PbR excluded: Yes

Background

NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating polycythaemia vera that is resistant to hydroxycarbamide or for people who cannot tolerate hydroxycarbamide because no evidence submission was received from Novartis Pharmaceuticals for the technology.

Recommendation

LMMG recommendation: Black
Click here to find the definitions for the colour classifications

Reason for decision:  Not recommended for prescribing on the NHS in Lancashire

Supporting documents:

NICE TA 356 - Ruxolitinib for treating polycythaemia vera (terminated appraisal)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Black

Black

Black

Black

Black